GlassScriptPhysician profile
Shauna A Mclaughlin
NPI 1417930157
$36,550.04
in general payments reported to CMS, 2019-2025
23 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $974 · 2023: $1,088 · 2024: $10K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $4,076 · Travel and Lodging: $4,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,615.00 |
| Food and Beverage | $4,075.89 |
| Travel and Lodging | $4,055.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,815.27 | 2023-2025 | |
| Allergan, INC. | $774.01 | 2021-2022 | |
| Merz North America, INC. | $331.63 | 2021-2025 | Xeomin |
| Optinose US, INC. | $292.04 | 2021-2023 | |
| Galderma Laboratories, L.P. | $289.17 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $238.61 | 2022-2024 | Dupixent |
| Glaxosmithkline, LLC. | $130.55 | 2021-2023 | Nucala |
| Novo Nordisk INC | $119.20 | 2022 | |
| Intersect Ent, INC. | $72.86 | 2021 | |
| Alk-Abello, INC | $70.42 | 2021-2023 | Grastek, Odactra |
| Hikma Pharmaceuticals USA | $65.78 | 2024-2025 | Ryaltris |
| Genzyme Corporation | $61.94 | 2021-2023 | |
| Eyevance Pharmaceuticals LLC | $61.88 | 2021 | |
| Phathom Pharmaceuticals, INC. | $30.95 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $26.95 | 2025 | Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.31 | 2025 | Zepbound |
| Ars Pharmaceuticals Operations, INC. | $24.16 | 2025 | Neffy |
| Davol INC. | $23.43 | 2021 | |
| Olympus America INC. | $21.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.29 | 2021 | |
| Amgen INC. | $20.06 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $18.37 | 2023 | |
| Phadia US INC. | $14.70 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shauna Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.